TABLE 3.
Ex vivo susceptibilities for paired isolates tested with 24 h of drug exposure at ring and trophozoite stage
| Drug |
P. falciparum |
P. vivax |
||||||
|---|---|---|---|---|---|---|---|---|
| na | Median IC50, nM (range) |
Pb | na | Median IC50, nM (range) |
Pb | |||
| Rings | Trophozoites | Rings | Trophozoites | |||||
| Chloroquine | 5 | 107.87 (60.17–163.58) | 142.71 (25.50–163.64) | 0.855 | 8 | 88.87 (41.85–190.17) | 778.18 (99.88–4,033.31) | 0.003 |
| Amodiaquine | 5 | 16.23 (4.86–201.77) | 17.96 (7.76–25.43) | 0.570 | 8 | 21.61 (5.69–39.47) | 53.22 (7.57–89.76) | 0.062 |
| Piperaquine | 5 | 21.85 (7.78–33.28) | 128.19 (13.80–359.25) | 0.044 | 8 | 20.88 (9.76–69.60) | 30.34 (18.08–205.52) | 0.076 |
| Mefloquine | 5 | 15.26 (4.74–46.88) | 17.26 (4.60–30.56) | 0.570 | 8 | 17.87 (8.17–41.00) | 37.06 (11.88–85.49) | 0.062 |
| Artesunate | 5 | 2.10 (0.74–5.11) | 3.87 (1.28–8.13) | 0.584 | 8 | 1.91 (1.21–4.57) | 7.20 (0.83–19.32) | 0.054 |
| PL69 | 5 | 90.39 (6.61–142.06) | 23.55 (7.25–92.82) | 0.465 | 7 | 17.59 (5.42–49.13) | 130.22 (10.26–268.15) | 0.018 |
| PL106 | 5 | 70.17 (62.24–110.05) | 50.67 (27.06–71.36) | 0.047 | 6 | 91.25 (54.35–126.84) | 172.48 (86.76–314.27) | 0.025 |
a
n, number of paired isolates.
b
Comparison of drugs tested at ring and trophozoite stage, respectively (Wilcoxon rank sum test).